Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Becton Dickinson and Co    BDX

BECTON DICKINSON AND CO (BDX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Becton Dickinson's 1st-Quarter Earnings Surge; Raises Year-View

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/05/2013 | 12:50pm CET
   By Saabira Chaudhuri 
 

Becton Dickinson & Co.'s (>> Becton, Dickinson and Co.) fiscal first-quarter earnings more than doubled as the medical device maker recorded revenue growth across all its segments, while margins also widened.

For the current year, Becton raised the bottom end of its revenue guidance, now expecting foreign currency neutral revenue growth starting at 4% versus its prior view starting at 3.5%. It now expects per-share earnings from continuing operations between $5.69 and $5.72, up from its prior view of earnings between $5.58 and $5.64.

The maker of products like surgical blades and test kits last spring struck a deal to sell the bulk of its lab-products business to Corning Inc. (>> Corning Incorporated) for $730 million in cash. Analysts who follow the company noted the sale stripped Becton Dickinson of a cash cow yet also gave it the freedom to focus on businesses with higher growth potential.

Ahead of the company's earnings announcement, analysts at Mizuho Securities downgraded Becton's ratings, noting that the company's life science research business--which makes up about 15% of sales--has been a drag on results for the past year, adding that they see no significant catalysts for the business in the near-term, as the academic market continues to be sluggish.

Still, Chief Executive Vincent A. Forlenza on Tuesday said the company is "starting to see notable results," adding that Becton is "growing revenues across our three segments, driving margin expansion and delivering a higher quality of earnings."

For the quarter ended Dec. 31, Becton Dickinson reported a profit of $625.4 million, or $3.13 a share, compared with $263 million, or $1.21 a share, a year earlier. Per-share earnings from continuing operations were $1.35 versus $1.14.

Revenue increased 3.7% to $1.9 billion. Analysts polled by Thomson Reuters most recently forecast earnings of $1.24 a share on revenue of $1.86 billion.

Gross margin widened to 52.9% from 50.8%.

Becton Dickinson's sales grew 3% in the U.S. and 4.3% internationally. The company's medical unit, its largest by revenue, reported sales rose 3.5%. The diagnostics business posted revenue growth 5%, while bioscience revenue was up 1.7%.

Shares closed Monday at $85.16 and were inactive premarket. The stock has risen 11% in the past three months.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Becton, Dickinson and Co., Corning Incorporated
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BECTON DICKINSON AND CO
12/11 BECTON DICKINSON AND : BD Establishes Product Security Partnership Program to En..
12/08 BECTON DICKINSON AND : U.S. Patents Awarded to Inventors in South Carolina (Dec...
12/08 BECTON DICKINSON AND : U.S. Patents Awarded to Inventors in Maryland (Dec. 8)
12/08 BECTON DICKINSON AND : U.S. Patents Awarded to Inventors in Utah (Dec. 8)
12/07 BECTON DICKINSON AND : "Safety Iv Catheter with V-Clip Interlock and Needle Tip ..
12/07 BECTON DICKINSON AND : Patent Issued for Plunger Assembly Including a Plunger Ro..
12/07 BECTON DICKINSON AND : Patent Issued for End of Injection Indicator for Injectio..
12/07 BECTON DICKINSON AND : Patent Issued for Safety Intravenous Catheter with Fricti..
12/07 BECTON DICKINSON AND : Patent Issued for Foldable IV Catheter Securement Dressin..
12/07 BECTON DICKINSON AND : Patent Issued for Graphics Control during Flow Cytometry ..
More news
News from SeekingAlpha
12/11 BECTON DICKINSON : A Fully Valued Healthcare Blue Chip Stock
12/05 Quanterix Files Proposed Terms For $50 Million IPO
12/01 10%-Plus Increases Expected From 7 Dividend Growth Companies In December
11/30 55 Dividend Growth Stocks Going Ex-Dividend Next Week
11/27 5 DIVIDEND INCREASES : November 20-24, 2017
Financials ($)
Sales 2018 12 769 M
EBIT 2018 3 238 M
Net income 2018 1 915 M
Debt 2018 3 159 M
Yield 2018 1,41%
P/E ratio 2018 27,60
P/E ratio 2019 24,22
EV / Sales 2018 4,16x
EV / Sales 2019 3,84x
Capitalization 49 925 M
Chart BECTON DICKINSON AND CO
Duration : Period :
Becton Dickinson and Co Technical Analysis Chart | BDX | US0758871091 | 4-Traders
Technical analysis trends BECTON DICKINSON AND CO
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 240 $
Spread / Average Target 9,7%
EPS Revisions
Managers
NameTitle
Vincent A. Forlenza Chairman & Chief Executive Officer
Thomas Polen President
Christopher R. Reidy EVP, Chief Financial & Administrative Officer
Ellen R. Strahlman Chief Medical Officer, EVP-Research & Development
Richard Pierle Chief Information Officer & Executive VP
Sector and Competitors